Medtronic
Medtronic's shift from device maker to healthcare technology company continues. Q1 FY2027, reported September 8, grew revenue 13.7% to $9.8B with adjusted EPS of $1.45, and full-year guidance rose to $5.94-6.00. On September 1 the company announced a $700M distribution partnership with Cornerstone Robotics for the CE-marked Sentire soft- tissue robot across China, Singapore and Europe, giving it a second robotics platform alongside Hugo - though that is a robotics-distribution agreement rather than a new AI capability, and it is deliberately not counted toward the AI score. GI Genius on NVIDIA IGX and the $200M AI Access platform remain the clearest AI-specific assets.
Scenarios
GI Genius to AI Access platform evolution creates recurring software revenue. Hugo robotics opens US market against dominant but high-priced Intuitive Surgical.
Intuitive Surgical's da Vinci moat is formidable. Broad but shallow AI portfolio risks being outmaneuvered by focused specialists.
Key Factors to Watch
- ●GI Genius + NVIDIA IGX integration creates autonomous endoscopy AI platform
- ●Hugo surgical robotics FDA cleared, entering US market
- ●7.5% revenue growth guidance — strongest among medtech
Score History
| Date | Score | Direction | Note |
|---|---|---|---|
| 2026-03-08 | 7.1 | Positive | Score 7.2→7.1 (formula reweight: sb 0.25→0.15, are 0.20→0.25, md 0.20→0.25, dr 0.20→0.25, aam 0.15→0.10) |
| 2026-03-08 | 7.2 | Positive | Score 6.6->7.2 (md 7->8, dr 5->4, aam 7->8). External research cross-ref: broadest device AI portfolio (Hugo cleared, GI Genius+NVIDIA, CathWorks $585M, MiniMed AI, AccuRhythm), AI Center of Excellence, 200+ GenAI initiatives |
| 2026-03-08 | 6.6 | Positive | Initial assessment from batch 3 research |
Healthcare Peers
Last researched: 2026-09-12
This is research and analysis, not financial advice. Scores reflect AI impact potential, not investment recommendations.